The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The prognostic relevance of altered antiglycan antibody profiles in the sera of primary melanoma patients.
A. Haimovic
No relevant relationships to disclose
M. W. Ma
No relevant relationships to disclose
M. I. Vuskovic
Other Remuneration - Patent for Immunoruler-Co-inventor
T. Miller
No relevant relationships to disclose
M. DiBenedetto
No relevant relationships to disclose
J. Grossman
No relevant relationships to disclose
R. L. Shapiro
No relevant relationships to disclose
A. C. Pavlick
No relevant relationships to disclose
R. S. Berman
No relevant relationships to disclose
H. I. Pass
Other Remuneration - Patent for Immunoruler-Co-inventor
M. Huflejt
Other Remuneration - Patent for Immunoruler-Co-inventor
I. Osman
No relevant relationships to disclose